Evaluation of the efficacy of a live attenuated vaccine (porcimune PRRS MLV) against porcine reproductive and respiratory syndrome virus in landrace piglets.
6 affiliations
- 1Departamento de Veterinaria y Zootecnia, Universidad de Guanajuato (UG), Guanajuato, 36500, Mexico.
- 2Centro de Investigación en Biotecnología Aplicada (CIBA), Instituto Politécnico Nacional (IPN), Tlaxcala, 90700, Mexico.
- 3Departamento de Investigación y Desarrollo, Lapisa, La Piedad, Michoacán, 59375, Mexico.
- 4Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, United States.
- 5Centro Nacional de Prevención y Control de Enfermedades (CENAPRECE), Secretaría de Salud México, Mexico City, 11800, Mexico.
- 6Centro de Ciencias Agropecuarias, Universidad Autónoma de Aguascalientes (UA), Aguascalientes, 20131, Mexico.
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) represents a constant challenge for the swine industry, both in Mexico and internationally, due to its high genetic variability and immunosuppressive capacity. This study evaluated the comparative efficacy of four modified-live vaccines in 3 to 4-wk-old seronegative piglets challenged intramuscularly with the heterologous PRRSV strain DAP150520 at 35 d post-vaccination (dpv; 0 d post-challenge, dpc). Fifty piglets were randomly allocated into five groups (n = 10/group): G1, ATCC-VR-2332; G2, SJO151012 ≥ 104 (Porcimune); G3, P129; G4, attenuated Nebraska ≥ 4.0; and G5, unvaccinated controls. Outcomes included ELISA seroconversion, qRT-PCR cycle threshold (Ct) values (PRRSV RNA detection), daily clinical scoring, BW, and gross lung lesions assessed using the modified Madec scale at 7 dpc. Group 2 (Porcimune) showed complete seroconversion from 21 dpv, controlled post-challenge viremia (cycle threshold [Ct] = 21.84 at 7 dpc), and a 57% reduction in lung lesions compared with controls. Group 1 (ATCC-VR-2332) also reached complete seroconversion by 21 dpv, whereas Group 3 (P129) showed early but fluctuating seroconversion and Group 4 (attenuated Nebraska) showed delayed and inconsistent seroconversion across sampling points, and Group 5 (control) remained seronegative until after challenge. Group 3 achieved a 63% reduction in lung damage, although with a more variable immune response. In contrast, G1, G4, and the control group showed lung lesions in 100% of animals after challenge. Post-challenge BW gain was significantly greater in G1 and G2 than in the unvaccinated control (one-way ANOVA, P = 0.023; Tukey's HSD, P = 0.039 and P = 0.045, respectively), meanwhile the control group showed a net BW loss after challenge. Overall, under these experimental conditions, Porcimune PRRS MLV was the only vaccine that differed significantly from unvaccinated controls in lung lesions, post-challenge BW gain and ELISA S/P ratio, supporting its protective potential against a heterologous PRRSV challenge.
Related
- Development and Efficacy Determination of an Attenuated Vaccine Against Channel Catfish Virus.
- Porcine Reproductive and Respiratory Syndrome Virus: Adaptive Immunity, Immune Evasion and Emerging Strategies for Disease Control.
- Evaluation of An I226R and A137R deletion mutant from a genotype I/II recombinant African swine fever virus strain as a live attenuated vaccine in pigs
- Development and Evaluation of Artificially Attenuated Corynebacterium pseudotuberculosis, Trueperella pyogenes, and Staphylococcus aureus Strains as Live Vaccine Candidates Against Ovine Caseous Lymphadenitis.
- Porcine reproductive and respiratory syndrome virus hijacks the non-canonical enzymatic function of PHGDH to arrest autophagic flux for viral replication
BibTeX
@article{garciamunguia2026evaluation,
title = {{Evaluation of the efficacy of a live attenuated vaccine (porcimune PRRS MLV) against porcine reproductive and respiratory syndrome virus in landrace piglets.}},
author = {Carlos A García-Munguía and María R Robles-López and Dhamar A Ramírez-Castillo and Raúl R Robles-de la Torre and Gloria P Galaviz-Martínez and José N Aguilar-Toribio and Alejandro Flores-Montenegro and Pablo Pineyro and Fabián Correa-Morales and Otilio García-Munguía and Miguel Ángel Plascencia-Espinosa and Alberto M García-Munguía},
journal = {Translational animal science},
year = {2026},
month = oct,
doi = {10.1093/tas/txag176},
url = {https://europepmc.org/article/MED/42997203},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Evaluation of the efficacy of a live attenuated vaccine (porcimune PRRS MLV) against porcine reproductive and respiratory syndrome virus in landrace piglets.
AU - Carlos A García-Munguía
AU - María R Robles-López
AU - Dhamar A Ramírez-Castillo
AU - Raúl R Robles-de la Torre
AU - Gloria P Galaviz-Martínez
AU - José N Aguilar-Toribio
AU - Alejandro Flores-Montenegro
AU - Pablo Pineyro
AU - Fabián Correa-Morales
AU - Otilio García-Munguía
AU - Miguel Ángel Plascencia-Espinosa
AU - Alberto M García-Munguía
PY - 2026
DA - 2026/10/28
JO - Translational animal science
DO - 10.1093/tas/txag176
UR - https://europepmc.org/article/MED/42997203
AB - Porcine reproductive and respiratory syndrome virus (PRRSV) represents a constant challenge for the swine industry, both in Mexico and internationally, due to its high genetic variability and immunosuppressive capacity. This study evaluated the comparative efficacy of four modified-live vaccines in 3 to 4-wk-old seronegative piglets challenged intramuscularly with the heterologous PRRSV strain DAP150520 at 35 d post-vaccination (dpv; 0 d post-challenge, dpc). Fifty piglets were randomly allocated into five groups (n = 10/group): G1, ATCC-VR-2332; G2, SJO151012 ≥ 104 (Porcimune); G3, P129; G4, attenuated Nebraska ≥ 4.0; and G5, unvaccinated controls. Outcomes included ELISA seroconversion, qRT-PCR cycle threshold (Ct) values (PRRSV RNA detection), daily clinical scoring, BW, and gross lung lesions assessed using the modified Madec scale at 7 dpc. Group 2 (Porcimune) showed complete seroconversion from 21 dpv, controlled post-challenge viremia (cycle threshold [Ct] = 21.84 at 7 dpc), and a 57% reduction in lung lesions compared with controls. Group 1 (ATCC-VR-2332) also reached complete seroconversion by 21 dpv, whereas Group 3 (P129) showed early but fluctuating seroconversion and Group 4 (attenuated Nebraska) showed delayed and inconsistent seroconversion across sampling points, and Group 5 (control) remained seronegative until after challenge. Group 3 achieved a 63% reduction in lung damage, although with a more variable immune response. In contrast, G1, G4, and the control group showed lung lesions in 100% of animals after challenge. Post-challenge BW gain was significantly greater in G1 and G2 than in the unvaccinated control (one-way ANOVA, P = 0.023; Tukey's HSD, P = 0.039 and P = 0.045, respectively), meanwhile the control group showed a net BW loss after challenge. Overall, under these experimental conditions, Porcimune PRRS MLV was the only vaccine that differed significantly from unvaccinated controls in lung lesions, post-challenge BW gain and ELISA S/P ratio, supporting its protective potential against a heterologous PRRSV challenge.
SN - 2573-2102
ER -